Stock Price & Analysis

Based on the analysis of Progyny's recent performance and market sentiment, it is recommended to hold PGNY stock as the company shows potential growth with its new Parent and Child Well-being program, but the stock's recent decline and mixed analyst sentiment warrant caution.

The price prediction for PGNY stock in 2025 is expected to trade between $20 and $24. The stock is currently showing a sideways trend with mixed technical signals, and without significant growth catalysts, it is likely to remain in this range.

The S1 support level for PGNY Stock is $21.11 ,The R1 resistant level for PGNY Stock is $22.94.

As of the end of day on 2025-04-02, the price of PGNY Stock was $23.09.

The target price for PGNY Stock according to analyst rating is 27.00, with the highest price target at 34.00 and the lowest at 23.00. Analysts have a Moderate Buy rating on PGNY Stock overall.

The market cap of PGNY is $2.0B.

Analysis and Insights

PGNY may be overvalued based on several factors:

1. High Valuation Metrics:

   • The price-to-earnings (P/E) ratio is elevated at 62.85, indicating a premium relative to earnings.
   • The EV/EBITDA ratio of 45.67 is also high, suggesting the stock is expensive compared to its earnings and debt levels.

2. Revenue and Profitability:

   • While revenue growth has been strong in Q1 and Q2 2024, it slowed significantly in Q3 and Q4, raising concerns about sustainability.
   • Net income declined sharply in Q3 and turned negative in Q4, signaling potential profitability challenges.

3. Technical Weakness:

   • The stock is trading below its 50-day and 200-day moving averages, indicating bearish momentum.
   • The MACD is negative, and the RSI is at 50.61, suggesting limited upside potential.

4. Recent News Impact:

   • The stock dropped 6.5% in pre-market trading on March 25, likely due to broader market declines and specific company-related news.
   • While PGNY launched a new Parent and Child Well-being program, it has not yet translated to positive price momentum.

5. Analyst Sentiment:

   • Analysts maintain a "Hold" rating, with mixed views on growth prospects.

Conclusion

PGNY appears overvalued given its high valuation metrics, inconsistent growth, and technical weakness. Investors may want to wait for a correction or clearer signs of stabilization before considering a purchase.

Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.

The predicted price for PGNY stock by 2030 is approximately $35 to $40. This estimate is based on the company's strategic expansion into integrated family-building solutions and recent analyst optimism, with price targets raised to reflect strong earnings and growth potential.

PGNY has a total of 563 employees.